Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Hose

Showing results (101-110 of 189) with videos related to

Pageof 19
Sort By:
Blood|February 29, 2008
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instabilityTilmann Bochtler, Ute Hegenbart, Friedrich W Cremer, et al.
Haematologica|July 11, 2019
Kinome expression profiling to target new therapeutic avenues in multiple myelomaHugues de Boussac, Angélique Bruyer, Michel Jourdan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysisMaud Condomines, Dirk Hose, Pierre Raynaud, et al.
Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24Olaf Christensen, Alaviana Lupu, Stefanie Schmidt, et al.
Oncoimmunology|November 15, 2021
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple MyelomaKim De Veirman, Janik Puttemans, Ahmet Krasniqi, et al.
British Journal of Haematology|August 3, 2021
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-upMarco Basset, Christoph R Kimmich, Nicholas Schreck, et al.
Cancer Genetics and Cytogenetics|August 17, 2005
High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISHFriedrich W Cremer, Mutlu Kartal, Dirk Hose, et al.
European Journal of Haematology|March 28, 2008
Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myelomaSebastian Belle, Fang Han, Maud Condomines, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Pageof 19

Showing results (101-110 of 189) with videos related to

Sort By:
Pageof 19
Blood|February 29, 2008
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instabilityTilmann Bochtler, Ute Hegenbart, Friedrich W Cremer, et al.
Haematologica|July 11, 2019
Kinome expression profiling to target new therapeutic avenues in multiple myelomaHugues de Boussac, Angélique Bruyer, Michel Jourdan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 22, 2007
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysisMaud Condomines, Dirk Hose, Pierre Raynaud, et al.
Journal of Hematology & Oncology|June 28, 2019
Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trialDirk Hose, Susanne Beck, Hans Salwender, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 2, 2009
Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24Olaf Christensen, Alaviana Lupu, Stefanie Schmidt, et al.
Oncoimmunology|November 15, 2021
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple MyelomaKim De Veirman, Janik Puttemans, Ahmet Krasniqi, et al.
British Journal of Haematology|August 3, 2021
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-upMarco Basset, Christoph R Kimmich, Nicholas Schreck, et al.
Cancer Genetics and Cytogenetics|August 17, 2005
High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISHFriedrich W Cremer, Mutlu Kartal, Dirk Hose, et al.
European Journal of Haematology|March 28, 2008
Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myelomaSebastian Belle, Fang Han, Maud Condomines, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Pageof 19